Page 10«..9101112..2030..»

You are currently browsing the Nano Medicine category

Addressing the potential impact of coronavirus disease (COVID-19) on Growth of Innovations in Nanomedicine Market by Major Players, Size, Industry…

§ April 29th, 2020 § Filed under Nano Medicine Comments Off on Addressing the potential impact of coronavirus disease (COVID-19) on Growth of Innovations in Nanomedicine Market by Major Players, Size, Industry…

Analysis Report on Nanomedicine Market

A report on global Nanomedicine market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Nanomedicine Market.

Request Sample Report @

Some key points of Nanomedicine Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Nanomedicine Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Nanomedicine Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Nanomedicine market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Nanomedicine market is analyzed and depicted in the report.

The global Nanomedicine market segment by manufacturers include

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Nanomedicine economic market. This included the CAGR value during the outlook period leading to 2025.

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

See original here:
Addressing the potential impact of coronavirus disease (COVID-19) on Growth of Innovations in Nanomedicine Market by Major Players, Size, Industry...

Read the Rest...

Oregon allergy season started early this year, thanks to mild winter, but long-term outlook isnt terrible –

§ April 28th, 2020 § Filed under Nano Medicine Comments Off on Oregon allergy season started early this year, thanks to mild winter, but long-term outlook isnt terrible –

The sunny spring days and appealing April weather have done wonders for your coronavirus blues, bringing a little light and a dose of happiness during an unsettling time.

But they also have been brutal for people with seasonal allergies, bringing sneezing, runny noses and itchy and watery eyes at an inopportune time.

The good news: This is not supposed to be a particularly bad allergy season, according to Shyam Joshi, an assistant professor of medicine at the OHSU School of Medicine who focuses on allergy and clinical immunology.

The bad news: Weve entered allergy season now a little bit earlier than normal, Joshi said. So its peaked earlier and the peak has lasted longer.

Oregons mild winter, combined with extra sunshine in February and March, have created a perfect storm for those who suffer from seasonal allergies, creating this longer-than-normal peak. Seasonal allergies originate from pollens, which are microscopic particles released in the air by trees, grass and weeds during their pollination season, according to the Columbia Asthma & Allergy Clinic. The pollens alone are not harmful, but immune systems of those who suffer from allergies perceive them to be, and they trigger an allergic reaction when they enter our airways.

Oregon is currently in the throes of tree season, which usually starts in February and extends through April. The state will soon enter grass season, which typically stretches from May to June. Tree season tends to overlap with cherry blossom season, leading many to mistakingly blame cherry blossoms for itchy eyes and incessant sneezing.

Right about the time those beautiful cherry blossoms start to flourish, nearby oak, elm and alder trees release loads of pollens in the air in search of reproduction. As those pollens scatter, allergy symptoms surface and many assume the cherry blossoms and other flowering trees are the culprits.

Allergies actually come from trees that dont flower, Joshi said. People see the cherry blossoms and think, Oh, it must be that. But its actually the oak tree right next to the cherry blossom.

Grass season is particularly tough for allergy sufferers in Oregon, because towns like Wilsonville and Corvallis produce grass seed and contain endless fields of grass. So as tree season transitions into grass season, many Oregonians endure months of suffering.

Things are more complicated in 2020, of course, because of the coronavirus pandemic.

This year people are paying attention to allergies more because of COVID, Joshi said. Is this from allergies? Is this COVID? It can be hard to figure out which one is which.

A variety of factors distinguish COVID-19 from ordinary allergies. According to the Centers for Disease Control and Prevention, COVID-19 may include the following symptoms after 2-14 days of exposure: Fever; cough; shortness of breath or difficulty breathing; chills; repeated shaking with chills; muscle pain; headache; sore throat; and new loss of taste or smell.

Conversely, common symptoms from seasonal allergies include sneezing, a runny or stuffy nose, watery and itchy eyes, ear congestion, postnasal drainage, and itchy sinuses, throat, or ear canals.

In theory, household dust mites can also cause symptoms similar to pollen allergies though Joshi said there was no data to support this which can complicate matters during statewide stay-at-home orders.

Emotional and physical stress can also amplify allergy symptoms and even the calmest folks are surely a bit more on edge during a pandemic.

If youve endured allergies in the past, odds are any symptoms youre currently experiencing are allergy-related. But there are ways to make sure.

If people are still concerned or having questions about symptoms, medical professionals are hosting virtual visiting, Joshi said. Phone and video visits are still an adequate way to get help and at OHSU, were still seeing the same number of patients as before. We dont want people to feel alone during this. Allergies can be quite debilitating for some people.

Joe Freeman | | 503-294-5183 | @BlazerFreeman | Subscribe to Oregonian/OregonLive newsletters and podcasts for the latest news and top stories

See the article here:
Oregon allergy season started early this year, thanks to mild winter, but long-term outlook isnt terrible -

Read the Rest...

How Coronavirus Pandemic Will Impact West Nile Virus Infections Medicine Value Projected to Expand by 2019-2027 – Jewish Life News

§ April 28th, 2020 § Filed under Nano Medicine Comments Off on How Coronavirus Pandemic Will Impact West Nile Virus Infections Medicine Value Projected to Expand by 2019-2027 – Jewish Life News

Study on the Global West Nile Virus Infections Medicine Market

The report on the global West Nile Virus Infections Medicine market reveals that the West Nile Virus Infections Medicine market is anticipated to grow at a CAGR of ~XX% during the forecast period (2019-2029). The report provides a thorough assessment of the impact of the COVID-19 pandemic on the current and future prospects of the West Nile Virus Infections Medicine market across various geographies. Further, the report provides accurate data related to the business continuity and contingency strategies adopted by leading market players operating in the West Nile Virus Infections Medicine market.

The quantitative and qualitative assessment of the various segments of the West Nile Virus Infections Medicine market enables stakeholders, investors, upcoming and established market players to devise robust business development strategies. The report tracks the recent developments within the West Nile Virus Infections Medicine market in terms of innovation, technological progress, regulatory framework, supply chain bottlenecks, and more.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @

Major Doubts Pertaining to the West Nile Virus Infections Medicine Market Addressed in the Report

Segmentation Analysis of the West Nile Virus Infections Medicine Market

The growth potential of the West Nile Virus Infections Medicine market in each region is accurately depicted in the report. The market attractiveness index included in the report enables readers to identify the most lucrative pockets within the West Nile Virus Infections Medicine market and make informed business decisions.

The report throws light on the adoption pattern of different products along with a thorough analysis of the pricing and supply-demand ratio of each product.

Competitive Landscape

The competitive landscape section of the report tracks the business proceedings of the key players operating in the West Nile Virus Infections Medicine market. The pricing, marketing, sales, and promotional strategies adopted by each market player is represented in the report. The contingency strategies of different players amidst the COVID-19 pandemic are touched upon in the presented report.

Market Segment AnalysisThe research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by Type, the West Nile Virus Infections Medicine market is segmented intoAGS-vBG-323CEL-1000FDX-000Others

Segment by ApplicationHospitalClinicOthers

Global West Nile Virus Infections Medicine Market: Regional AnalysisThe West Nile Virus Infections Medicine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the West Nile Virus Infections Medicine market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EGlobal West Nile Virus Infections Medicine Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.The major players in global West Nile Virus Infections Medicine market include:CEL-SCI CorpFabentech SAHemispherx Biopharma IncKineta IncNanotherapeutics IncPlex Pharmaceuticals IncTheravectys SA

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]

Key Findings of the Report

You can Buy This Report from Here @

Original post:
How Coronavirus Pandemic Will Impact West Nile Virus Infections Medicine Value Projected to Expand by 2019-2027 - Jewish Life News

Read the Rest...

How Coronavirus Pandemic Will Impact Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2026 – Jewish Life News

§ April 28th, 2020 § Filed under Nano Medicine Comments Off on How Coronavirus Pandemic Will Impact Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2026 – Jewish Life News

Analysis of the Global Regenerative Medicine Products Market

The report on the global Regenerative Medicine Products market reveals that the market is expected to grow at a CAGR of ~XX% during the considered forecast period (2019-2029) and estimated to reach a value of ~US$XX by the end of 2029. The latest report is a valuable tool for stakeholders, established market players, emerging players, and other entities to devise effective strategies to combat the impact of COVID-19

Further, by leveraging the insights enclosed in the report, market players can devise concise, impactful, and highly effective growth strategies to solidify their position in the Regenerative Medicine Products market.

Research on the Regenerative Medicine Products Market Addresses the Following Queries

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @

Competitive Landscape

The competitive landscape section offers valuable insights related to the business prospects of leading market players operating in the Regenerative Medicine Products market. The market share, product portfolio, pricing strategy, and growth strategies adopted by each market player is included in the report. The major steps taken by key players to address the business challenges put forward by the novel COVID-19 pandemic is discussed in the report.

Regional Landscape

The regional landscape section provides a deep understanding of the regulatory framework, current market trends, opportunities, and challenges faced by market players in each regional market. The various regions covered in the report include:

End-User Assessment

The report bifurcates the Regenerative Medicine Products market based on different end users. The supply-demand ratio and consumption volume of each end-user is accurately depicted in the report.

Market Segment AnalysisThe research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by Type, the Regenerative Medicine Products market is segmented intoCell TherapyTissue EngineeringBiomaterialOthers

Segment by ApplicationDermatologyCardiovascularCNSOrthopedicOthers

Global Regenerative Medicine Products Market: Regional AnalysisThe Regenerative Medicine Products market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the Regenerative Medicine Products market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EGlobal Regenerative Medicine Products Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.The major players in global Regenerative Medicine Products market include:AcelityDePuy SynthesMedtronicZimmerBiometStrykerMiMedx GroupOrganogenesisUniQureCellular Dynamics InternationalOsiris TherapeuticsVcanbioGamida CellGolden MeditechCytori TherapeuticsCelgeneVericel CorporationGuanhao BiotechMesoblastStemcell TechnologesBellicum Pharmaceuticals

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]

Essential Findings of the Regenerative Medicine Products Market Report:

You can Buy This Report from Here @

How Coronavirus Pandemic Will Impact Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2026 - Jewish Life News

Read the Rest...

MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Prot –

§ April 28th, 2020 § Filed under Nano Medicine Comments Off on MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Prot –

MagForce AG / Key word(s): StudyMagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

27-Apr-2020 / 23:51 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

Berlin, Germany, and Nevada, USA, April 27, 2020 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., today announced that FDA approval for a streamlined trial protocol, for the next stage of the Company's pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer was received. The next stage of the clinical trial is being initiated with three well-respected urological centers in Texas, Washington and Florida who actively enrolled patients in Stage 1.

The streamlined procedure will allow the patient treatment to be completed within one day at one of MagForce's three out-patient treatment facilities and is possible because of limited side effects that were observed at each step of the procedure in Stage 1.

The next stage of the study will be conducted in phases to ensure early on that the minimal side effects observed in Stage 1, with a drawn out procedure, are maintained in the streamlined one day procedure. Treatment of the first 5 to10 subjects should be sufficient to affirm the minimal side effects as expected.

COVID-19 impact: While there are many restrictions that have been applied such as "Shelter at Home" and eliminating state to state travel via car or via plane; however, MagForce is still working diligently with its physician investigators. Exemptions exist for healthcare workers, such as MagForce's USA staff at MagForce USA clinical facilities. Clearly MagForce USA can conduct the trial in its out-patient facilities and has developed COVID-19 infection control procedures for staff and study subjects. All this effort has caused a certain delay but MagForce is confident the next stage of the clinical trial will not be unduly delayed since MagForce USA will conduct the trial from its facilities.

MagForce is still hopeful that the COVID-19 pandemic will not cause significant delay beyond 2020 to complete this single-arm clinical trial.

- End of Insider Information -

Contact:MagForce AG, Max-Planck-Strae 3, 12489 BerlinBarbara von FrankenbergVice President Communications & Investor RelationsT +49-30-308380-77E-Mail:


This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

27-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at

Go here to read the rest:
MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Prot -

Read the Rest...

Nanomedicine Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

§ April 27th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Nanomedicine Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.

It offers detailed research and analysis of key aspects of the global Nanomedicine market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Nanomedicine market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Nanomedicine market is carefully analyzed and investigated by market analysts.

For Better Understanding, Download Sample PDF Copy of Nanomedicine Market Research Report @

**Our SAMPLE COPY of the report gives a brief introduction of the Nanomedicine market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

The Major Players in Global Nanomedicine Market:

Global Nanomedicine Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @

Nanomedicine Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Nanomedicine industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Nanomedicine industry.

-> Furthermore, we will help you to identify any crucial trends to predict Nanomedicine market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Nanomedicine market.

Have Any Query? Ask Our Expert@

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Nanomedicine market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Nanomedicine market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Nanomedicine Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Nanomedicine Market Size, Nanomedicine Market Growth, Nanomedicine Market Forecast, Nanomedicine Market Analysis

Our Trending Reports

Commercial Greenhouse Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Deep Learning Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Digital Out Of Home Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See original here:
Nanomedicine Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Read the Rest...

What’s Happening Inside The Cells Of A Coronavirus Patient –

§ April 27th, 2020 § Filed under Nano Medicine Comments Off on What’s Happening Inside The Cells Of A Coronavirus Patient –

There are many big numbers associated with the coronavirus pandemic: tens of thousands have lost their lives, and millions have filed for unemployment. But there's also much smaller story playing out inside the cells of those who contract the virus.

This microscopic, unpredictable story is what makes the coronavirus so deadly, and developing a treatment so challenging, experts say.

Unlike bacteria or fungi, viruses cannot live on their own they require host cells to function. When viruses use human cells as hosts, they completely take over all of the metabolic pathways of the cell to replicate itself, explained David Leib, chair of microbiology and immunology at Dartmouth College.

It would be as if somebody walked into a car factory and snapped his fingers and said suddenly, You're making Twinkies! he said.

The coronavirus can attack the first cells it encounters in our nose or throat.

It takes the virus roughly 10 minutes to get inside that cell and then to begin its replication cycle, Leib said.

Then, he said, it takes eight to 10 hours to produce hundreds of copies of itself that go on to infect other cells in our bodies.

But while the virus is replicating and spreading, people are not necessarily aware. The World Health Organization says it can take between one and 14 days for a person to notice symptoms; the average is five days. And some people who are infected never develop symptoms.

Leib said its this period of time, when you do not feel sick but the virus is replicating, that makes coronavirus so dangerous and so hard to stop.

You are a walking bottle of virus, he said. Any of your respiratory droplets would be quite infectious during that time, despite the fact that you feel well enough to go out and go to the store.

After the virus breaks into your cells, some patients develop symptoms. However, many of the symptoms, including fever and aches, are actually a product of your immune system fighting off the virus rather than the virus itself.

Many people have mild illness and after a week or so they feel a lot better, said Shira Doron, an infectious disease doctor and epidemiologist at Tufts Medical Center.

For most people, Doron said, that mild illness seems to be it. The persons immune system is able to see that the virus is hijacking cells and stop it.

But a small percentage of people have a second phase of the illness. They seem to be getting better until their symptoms begin escalating. The Centers for Disease Control and Prevention warns that clinicians should be aware of the potential for some patients to rapidly deteriorate one week after illness onset.

For many of these coronavirus cases in which symptoms become severe the bodys response to the virus may actually be more damaging than the virus itself.

We actually, occasionally, find that people who are really, really sick from COVID-19, don't even have a positive test at that point, Doron said. It's not the virus really anymore that's causing the symptoms. It's the immune response to that invasion. We call it the cytokine storm.

Cytokines are proteins that act like an alarm in the immune system, sending out signals and calling in reinforcements to fight an invader. In a cytokine storm, although the fight might need just one military unit, the alarm keeps going off and a massive army shows up.

This immune overreaction is causing collateral damage. It's like friendly fire, explained Leib. It's just like any other urgent situation an overreaction can be just as damaging as not reacting at all.

Too many cells are recruited to fight off the invader, and the cells fail to respond effectively.

"The cells become exhausted very quickly, said Galit Alter, a professor of medicine at the Ragon Institute of Massachusetts General Hospital, MIT and Harvard. Theyre getting stimulated so hard by all these cytokines that the cells at some point almost poop out. And they are not able to completely participate in that antiviral response.

In the lungs, this can look like a lot of inflammation there is fluid accumulation where there is supposed to be air. That makes it very challenging for oxygen to transfer into the blood.

Unlike humans, Leib said, bats which experts think are the source of COVID-19 dont get cytokine storm. "This lack of cytokine storm in bats may explain why they don't get sick, but we do, he said.

Leib said one of the challenges of combating COVID-19 in humans is the fact that viruses hijack our cells.

This is really the crux of the reason why it has been so hard to develop antiviral drugs, because almost any drug that will stop viruses dead in [their] tracks will also stop our cells dead in their tracks, he said.

Doron, Alter and Leib emphasized how much there is still to learn about the virus. But Leib believes our best hope for fighting it is a vaccine that trains the immune system to recognize and eliminate the coronavirus before it can take hold and before the immune system can call in that army.

Here is the original post:
What's Happening Inside The Cells Of A Coronavirus Patient -

Read the Rest...

Five Innovative Technologies Improving Pharmaceutical Wastewater Treatment – EuroScientist

§ April 27th, 2020 § Filed under Nano Medicine Comments Off on Five Innovative Technologies Improving Pharmaceutical Wastewater Treatment – EuroScientist

All living things depend on water. It covers most of the planet and doesnt just support life itself, but fuels many aspects of peoples way of living. Water is as central to modern industry as it is to survival. However, this creates a few complications.

As people use water in various industrial processes, they tend to pollute it. To protect the environment and ensure people have clean drinking water, people need to treat wastewater. In some sectors, like pharmaceuticals, purifying wastewater is critical.

The pharmaceutical industry, like many other areas of life, relies on clean water. To make different drugs safe to ingest, chemists need to use ultra-pure water in the production process. Industry standards like the European Pharmacopoeia even set regulations for water purity in pharmaceuticals.

Pharmaceutical companies arent merely concerned with treating water before they use it, either. As they use this substance in various processes, it comes out full of pollutants, as youd expect of any industry. However, the contaminants that come out of pharmaceutical work can be particularly dangerous to both people and nature.

The manufacturing process introduces a lot of chemical contaminants, both organic and synthetic. Drug companies need to use high-tech purification methods to make sure none of these chemicals gets outside. As a result, the industry is always looking into new technology to clean wastewater.

Here are five technologies improving pharmaceutical water treatment.

One of the most popular emerging solutions to treat pharmaceutical wastewater is membrane separation. You can find several ways to use membranes for purification, but they all involve forcing water through a film full of microscopic holes. Liquid passes through, but contaminating particles get stuck.

Todays membranes can filter out far smaller contaminants than their older counterparts. The fibres that make up these membranes, full of millions of tiny pores, would be impossible without modern manufacturing. However, the sophisticated process of making them pays off.

Membrane separation techniques like reverse osmosis can remove 99.5% of pollutants from water. This impressive figure is only possible with pores that are just a fraction of a micron in size.

Another increasingly popular purification solution is irradiation. As the name suggests, this process involves exposing wastewater to radiation to kill off organic contaminants and break apart inorganic ones. Scientists can use any number of different sources for irradiation, from gamma rays to UV light.

Irradiation is especially ideal for taking care of pollutants like hormones and antibiotics. However, its usefulness applies to every kind of contaminant, not just these organic compounds. Some techniques, like ionizing irradiation, can reach almost 100% effectivenessin removing pollutants from wastewater.

As you mightve guessed, irradiation does come with a few risks. Too much can be hazardous to human health. Similarly, too low a dose can create dangerous by-products. Todays labs are sophisticated enough to ensure chemists apply the right dosage every time.

Nanotechnology, working with objects smaller than 100 nanometers, is one of the most exciting developments in science. Youll often hear about nanotechnology in medicine and engineering, but some chemists use it to clean water too. Using nanoparticles to absorb pollutants from water has seen a lot of growth lately.

People have been using things like charcoal to purify water through absorption for a long time. Nanoparticle treatment uses this same concept but on a much smaller scale. It uses nanotubes made of absorbent material like carbon to pull even the smallest pollutants out of water.

Nanotechnology is still relatively expensive, so this process isnt as widespread as others. But with continued development, it will become more affordable and more viable.

Some pharma companies turn to biology to purify their wastewater. One of the most popular and promising biological approaches to water purification is bioaugmentation. With this method, scientists introduce a mix of microorganisms to the liquid that breaks down and removes contaminants.

These microorganisms include enzymes and certain, safe strains of bacteria. These organisms naturally degrade pollutants like oils or carbon substrates, so they provide an organic method of cleaning water. Bioaugmentation is usually part of a multi-step process, though, as chemists need to remove the microorganisms after the fact.

Sometimes bioaugmentation has other benefits, too. On top of removing harmful pollutants, it can release nutrients as a by-product, making water healthier all around. This process isnt as standard as some of the others, but it is steadily growing.

Some of the most effective modern methods of water purification are hybrid solutions. More and more pharma companies opt for membrane-bioaugmentation hybrid technology instead of picking one part of the process over the other. Membrane bioreactors are an increasingly widespread example of this technology.

Membrane bioreactors first feed wastewater through a device called a bioreactor. These containers host active biological elements, like the bacteria and enzymes found in bioaugmentation. After the bioreactor, water moves through a membrane, which filters out the microorganisms as well as any leftover contaminants.

The water membrane bioreactors produce is among the cleanest of any treatment process. In addition to that, these systems also allow chemists to recycle some of the removed materials from the water. That added benefit makes hybrid solutions some of the most economically viable options for pharma companies.

The pharmaceutical industry can produce a lot of harmful pollutants in its water usage. Thankfully, however, water treatment methods improve all the time, so pharma companies can use water without endangering the environment. These purification techniques are also economically enticing for the pharma industry.

By thoroughly cleaning their water, pharmaceutical companies can recycle it in their processes, saving money. These modern purification methods are useful enough that they can produce the near-perfect level of purity pharmaceutical processes require. By recycling water, these companies also reduce their amount of water waste, further protecting the environment. Pharmaceutical wastewater, if untreated, poses a threat to both humans and nature. Yet advanced treatment technology makes pharmas water use environmentally safe and economically viable.

Featured image credit: Louis Reed

Like Loading...

Related Posts

Follow this link:
Five Innovative Technologies Improving Pharmaceutical Wastewater Treatment - EuroScientist

Read the Rest...

Medical Radiation Shielding Market New Era Of Industry and Forecast 2017-2025 – Latest Herald

§ April 27th, 2020 § Filed under Nano Medicine Comments Off on Medical Radiation Shielding Market New Era Of Industry and Forecast 2017-2025 – Latest Herald

Global Medical Radiation Shielding Market: Snapshot

The International Atomic Energy Agency describes the process of radiation protection or radiation shielding as the protection of humans from the negative impact they may receive when exposed to harmful values of ionizing radiation. For the sake of simplicity, most radiation shielding refers to the protection of human beings alone, as most technology that involves ionizing radiation refers to human contact. Ionizing radiation finds a growing scope of applications in the medical fields, due to which there is a very high chance of people suffering from radiation poisoning. It holds a strong potency of permanently damaging human tissues by affecting them at a microscopic level. The more common signs of exposure to ionizing radiation include radiation sickness, skin burns, and increased chances of cancer. The level of radiation exposure and the time duration of exposure can determine the signs of sickness that a patient may show.

Get Sample Copy of the Report @

There are different kinds of ionizing radiations and their reaction with the same radiation shield will be likewise different. This is why it is extremely important to use specific types of shielding materials against the different types of radiation. As a result, the global medical radiation shielding market needs to provide different types of shields for different types of radiation. It should also be noted that the shielding power will depend on the thickness, or the number of sheets used to create the shield. The calculations required for ascertaining the thickness of a radiation shield use a unit called halving thickness.

Global Medical Radiation Shielding Market: Overview

The global medical radiation shielding market is expected to grow at a positive rate between 2017 and 2025. The demand for medical radiation has shown a considerable surge in the last few years in response to the increasing incidence of chronic ailments, especially cancer. As per the World Health Organization, the new cases of cancer are expected to rise by 70% in the next two decades. The chronic ailment will therefore remain a leading cause of death across the world. Consequently, the demand for advanced treatment for fighting cancer is expected to remain high through the forecast period, thereby giving impetus to the global medical radiation shielding market.

The global medical radiation shielding market can be broadly classified on the basis of solution, product, end user, and region. For instance, sheet lead, shields, lead bricks, booths, barriers, lead lined doors & windows, x-ray rooms, lead glass, lead lined plywood, and lead curtains are a few of the key products available in the global medical radiation shielding market. By solution, the market can be bifurcated into diagnostic shielding and radiation therapy shielding.

The report covers growth drivers and restraints influencing the markets trajectory across all its segments. To present a holistic study, the report includes information obtained through proven research methodologies and from trusted industrial sources. It gauges the effect of Porters five forces and examines the investment feasibility for new players. Overall the report is intended to provide a clearer perspective of the global medical radiation shielding market to the readers.

Request TOC of the Report @

Global Medical Radiation Shielding Market: Trends and Opportunities

Various factors support growth witnessed in the global medical radiation shielding market. The rising incidence of cancer will remain the chief driver, besides which the market will gain from the increasing use of nuclear medicine and radiation therapies for accurate diagnosis and cancer treatment. In addition, factors such as the increasing number of installation bases and diagnostic imaging centers, and the growing awareness about safety among people working in radiation-prone environment will aid the markets expansion. The market is also likely to benefit from the expansion of the healthcare industry worldwide and the upward moving number of people covered under insurance schemes.

Strong growth witnessed in emerging nations will create an array of opportunities for the medical radiation shielding market. However due to the high cost of MRI scanners, it may witness a few restraints in the forthcoming years.

Global Medical Radiation Shielding Market: Regional Outlook

Regionally, the global medical radiation shielding market will continue witnessing lucrative opportunities in North America, followed by Europe and Asia Pacific. Being a developed market, North America is an attractive hub for enterprises operating in the medical radiation shielding market. However, Asia Pacific will gradually emerge at fore during the course of the forecast period due to the growth witnessed by the market in India and China. Moreover, the rising awareness about radiation safety and the increasing funding in the healthcare sector will fuel the adoption of the medical radiation shielding technology in Asia Pacific.

Global Medical Radiation Shielding Market: Vendor Landscape

Some of the leading companies operating in the global medical radiation shielding market are Nelco, Inc., ETS-Lindgren, Radiation Protection Products, Ray-Bar Engineering Corp, Amray, and Global Partners in Shielding, Inc. among others. Policies adopted by the leading market players have a profound influence on overall operations. The report therefore includes their in-depth profiles covering recent marketing strategies, mergers and acquisitions, and product port-portfolios.

See the rest here:
Medical Radiation Shielding Market New Era Of Industry and Forecast 2017-2025 - Latest Herald

Read the Rest...

Should masks be mandatory in public to stop the spread of COVID-19? –

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on Should masks be mandatory in public to stop the spread of COVID-19? –

This is an excerpt fromSecond Opinion, aweeklyroundup of eclectic and under-the-radar health and medical science news emailed to subscribers every Saturday morning.If you haven't subscribed yet, you can do that byclicking here.

A growing chorus of experts is calling for the widespread use of masks to slow the spread of COVID-19 and suggesting it may be a key factor in why some countries seemingly have their outbreaks under control while others are completely overwhelmed.

The World Health Organization does not officially recommend the general publicuse masks as a wayto reduce spreading the virus, only saying that if they do decide to use masks, they should do so "safely and properly."

"We encourage countries that are considering the use of masks for the general population to study their effectiveness, so we can all learn from their experience," a spokesperson for WHO said in a statement to CBC News.

"Currently, there is insufficient evidence for or against the use of any type of mask among healthy people in public settings. As new information and evidence about masks and non-medical masks emerges, WHO will update existing guidance."

WHO does recommend medical masks, respirators and other personal protective equipment (PPE) in health care settings, but says only people who are sick or caring for a sick person at home should use them in the community.

WATCH | An epidemiologist explains why masks are effectivefor asymptomatic carriers

"Masks alone cannot stop the pandemic. Countries must continue to find, test, isolate and treat every case and trace every contact," WHO Director-General Tedros Adhanom Ghebreyesus said earlier this month.

"Mask or no mask, there are proven things all of us can do to protect ourselves and others:keep your distance, clean your hands, cough or sneeze into your elbow,and avoid touching your face."

But the specific language WHO uses has come under fire from experts who suggest that even non-medical masks could be beneficial in curbing the spread of the virus or, at the very least, couldn't hurt.

Babak Javid, a professor at the Tsinghua University School of Medicine in Beijing and a consultant in infectious diseases at Cambridge University Hospitals in the U.K., thinks there's a double standard in WHO's messaging.

Yes, he says, "there's no direct evidence that masks can prevent transmission."

"But there's no direct evidence that hand-washing can prevent the transmission of COVID or lockdowns can prevent the transmission of COVID because none of those trials have ever been done in the context of COVID."

Javid said there is a "logical gap" in WHO's recommendation, because it doesn't take into account the significant number of asymptomatic or pre-symptomatic carriers of the virus in the general population, also known as "silent spreaders."

Asymptomatic carriers are those who show no symptoms, while pre-symptomatic carriers are people who have not yet displayed symptoms usually in the first few days of infection.

"What I think is indisputableis that the face covering can reduce the amount of both droplets and virus that we can transmit," he said.

Emerging research has revealed more about how the virus spreads from person to person, suggesting it doesn't just transmit through coughingbut also through simply talking.

A U.S. National Institutes of Health study published as a research letter in the New England Journal of Medicine this week provided visual evidence that "speech-generated droplets" can become suspended in the air and inhaled by other people, potentially exposing them to viruses like the one responsible for COVID-19.

That provides some preliminary evidence that the potentially deadly coronavirus, also known as SARS-CoV-2, could be transmitted between people just by speaking normally.

"There's plenty of research showing that even just when we talk and breathe, we release these very small respiratory droplets, smaller than we can see," said Dr. Linsey Marr, an expert in the transmission of viruses by aerosol at Virginia Tech in Blacksburg, Virginia.

"Masks really could help make a difference because they will if you are sick without knowing it block those droplets from flying into the air and then staying in the air or contaminating surfaces."

A paper by researchers in China set to be published in July in the U.S. Centers for Disease Control and Prevention's journalEmerging Infectious Diseases, found an infected individual without symptoms was apparently able to spread the virus to nine others at a restaurant in Guangzhou, China.

The direction the air-conditioning system was blowing may have helped transport the virus particles to other diners, who otherwise had no contact with one another, while those elsewhere in the restaurant who weren't near the airflow didn't get sick.

The study has limitationsbecause the findings were not corroborated with experiments to simulate the airborne transmission. Still, the research is raising concern.

"That was pretty strong evidence for the potential that transmission is happening through these microscopic respiratory droplets that can stay floating in the air for a long enough time to kind of go back and forth over the tables," Marr said.

Last week, Transport Canada made it mandatory for all air passengers to wear non-medical masks or face coverings over their mouth and nose during travel.

Passengers on boats are "encouraged to wear non-medical masks or face coverings whenever possible," while train or bus riders are also "strongly encouraged" to do the same.

But the Public Health Agency of Canada only recently changed course on its recommendations to Canadians on the effectiveness of non-medical masks, previously saying masks should only be worn by health care workers.

"Wearing a non-medical mask is an additional measure that you can take to protect others around you," Canada's Chief Public Health Officer Dr. Theresa Tam said on April 6 while warning that a non-medical mask doesn't necessarily protect the person wearing it.

"A non-medical mask can reduce the chance of your respiratory droplets coming into contact with others or landing on surfaces," Tam said. "The science is not certain, but we need to do everything that we can and it seems a sensible thing to do."

PHAC also says non-medical masks are "not a substitute for physical distancing and hand-washing," but can protect those nearby "even if you have no symptoms."

But some experts say that given that significant role asymptomatic and pre-symptomatic carriers of the virus play in the spread of the virus, Canada should be mandating the use of non-medical masks in public, the way other countries have.

"Public health officials are saying there's no evidence that the mask is going to keep you from getting the disease, but I also think it's important to recognize that absence of evidence is not evidence of absence," said Dr. Joe Vipond, a Calgary emergency department physician.

"Even a small decrease in the risk of me getting the disease is still really important from a population level."

Asian countries that have successfully dropped their curve of new COVID-19 cases, like South Korea, Taiwan and China, all have widespreadmask usage, while the Czech Republic recently implemented mandatory maskmeasures and saw case fatality rates drop, Vipond wrote in a recent op-ed for Maclean's magazine.

There are numerous factors as to why a given country can become overwhelmed by the virus, including the onset of outbreaks, the accuracy of reporting, backlogs in testing, the age of thepopulation and the effectiveness of containment measures.

But Javid said that while this is still just correlative evidence, it could be one reason why countries like Taiwan, which doesn't have total lockdown measures in place but does have widespread mask usage, has a much lower incidence of COVID-19 than other countries like Sweden, for example, where masks are less commonly used.

Jeremy Howard, a University of San Francisco researcher and the co-founder of Masks 4 All, said Japan is another example of a densely populated region with widespread public mask wearing and low levels of COVID-19 despite not prioritizing physical distancing or testingcompared with a place like New York.

"There's all this evidence, which strongly suggests, as part of the suite of tools we have available, wearing a mask appears to be astonishingly powerful, and the cost is nearly zero," he said.

"And when we compare the level of evidence we have to something like washing hands, it's vastly, vastly, vastly, vastly higher."

While masks are not a "magic bullet" in curbing the spread of the virus and more research still needs to be done on their effectiveness, Javid said they can be used in conjunction with other measures like physical distancing and widespread testing to slow the spread.

"To get over the COVID problem we're going to need a multi-pronged approach. To me, what's attractive about masks is that they're cheap, they're probably effective and they allow economic activity," he said.

"We can't stay in lockdown forever, so to me,the downsides are so minimal compared to the potential upsides."

Should masks be mandatory in public to stop the spread of COVID-19? -

Read the Rest...

How covid-19 birthed the millennial caregiver – Livemint

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on How covid-19 birthed the millennial caregiver – Livemint

Anticipatory grief is that feeling we get about what the future holds when were uncertain. Usually it centres on death. We feel it when someone gets a dire diagnosis or when we have the normal thought that well lose a parent someday."

These words have resonated with people across the world. Accurately deconstructing the pit in the stomach, alternating waves of distress and panic, since the covid-19 pandemic really hit India, Kessler gave coherent voice to the scramble of feelings people seemed to be experiencing. The interview hit those who have parents over the age of 60, and those who have parents over the age of 60 with co-morbidities, particularly hard.

The interview was all over social media, shared rapidly on 23 March, when it was first published, and in the weeks that followed as the lockdown came into force two days later.

The 60-plus group is most at risk in a covid-19 world. The virus, in its microscopic enormity, has revealed the fragility of a mother or father who had not been seen as elderly", the vulnerability of individuals whose mortality had seemed distant enough so far.

Angshuman Chaudhary, 27, has lived away from his Guwahati home for nearly 11 years. The researcher at the Institute of Peace and Conflict studies (IPCS) in Delhi was to visit his parents before the lockdown was imposed. His mother suffers from asthma, father from arthritis, and both parents are mildly diabetic. While they live close to friends in an apartment complex, the lockdown has isolated them almost entirelyfor now its the two of them and their three cats.

It has all started bothering me now, especially after this, the covid-19 outbreak and the lockdown, where mobility is further restricted. They need more help now in terms of doing everyday things," says Chaudhary. When his mother had to be hospitalized recently owing to a severe stomach infection, Chaudharys father had to do all the shuttling, cooking and getting food to the hospital. A hospital is a place where you are prone to infections right now," he says. Usually I dont feel homesick or anything but these days there is a latent anxiety. There is this sense that as soon as the lockdown is over, all I would really like is to go home."

In Visakhapatnam, Lingam Vaidehi, 37, moved back home from Delhi shortly after her mother had to spend three weeks in the ICU owing to a pulmonary embolisma clot exploded in her lung". She has now been cooped up with her parents for over five weeks, ensuring her mother, who is 60, is taking her medicines, has her BiPap and oxygen concentrator handy, and ensuring no one goes in or out of the house other than her sister, who lives a few minutes away.

Millennials in India have rarely been seen as caregivers but with the covid-19 pandemic widening the ambit of who is now vulnerable, they suddenly find themselves anxious, even about financially and otherwise independent parents. Whether it is Chaudharys unlikely homesickness or Vaidehi and her family organizing medicines four months in advance and putting off routine procedures, this generation now finds itself in an unfamiliar role.

Initially, every day they had to draw her blood, to check the international normalized ratio (INR), based on which she would take a dose of the medicine prescribed," says Vaidehi. But though the frequency of these tests has come down, the family has decided to suspend them altogether and ensure her vitamin K intake is negligiblethis means no potatoes, tomatoes, green vegetables. During lockdown, this kind of diet is neither easy to maintain nor procure, but they have weighed the risks. Now she can take signs from her bodyif her palms turn blue or she gets dizziness, the balance is off. But a lab technician coming in or her going out to get blood drawn is something that makes us very uncomfortable right now," says Vaidehi.

She adds: I dont think we will see a very dire state. We are hoping she will get to keep up through this."

Not even a statistic

According to the World Population Ageing Report 2017 released by the population division of the UNs department of economic and social affairs, India had approximately 120 million people over the age of 60. But there is no assessment of caregiving for India, unlike the US, where theAARP, a non-profit interest group dedicated to empowering people to choose how they live as they age", showed that millennials make up 25%one in fourof the 40 million unpaid caregivers". In India, the focus so far has been on the sandwich generation"and largely womenwhich constituted those between the ages of 30-50, who have to take care of their children and their elderly parents and in-laws.

The problem is that we dont have data in India from the perspective of caregivers, especially millennials, so everything then becomes anecdotal," says Lekha Subaiya, demographer and assistant professor at the Population Research Centre, Institute for Social and Economic Change, Bengaluru. Theres a lot of research on ageing in Western countries because ageing is a much more pressing issue for them. For us, that hasnt happened yet so everything that has been written, or the research here, is largely about how many old people there are and what percentage has chronic morbidities," she adds. According to the UN, however, the share of older personsthose aged 60 or abovein Indias population is projected to increase to nearly 20% by 2050.

For millennials, especially those in their 20s who have just started out on their careers, the pandemic has brought into stark focus the need to balance the logistics of parent care with the needs of their children, if any, finances and Zoom calls..

Pune-based Mayuri Purkayastha, a young fellow at the non-profit Teach For India, believes you need to become financially independent faster so your parents dont have to support you during their retirement. When people are taking a gap year or travelling, you are in a rush to do something or the other to ensure you are not a financial burden on them," says the 23-year-old. Its never explicitly stated by parents but you feel the hesitation yourself in taking support."

And that is exactly what she did. Purkayastha finished her studies and started worktoday, she is financially independent. My parents are very strong, practical people and they want me to grow up and be the same. My mother has seen the worst in life so she doesnt believe in mollycoddling anyone."

In 2018, Purkayasthas mother was diagnosed with B-cell lymphoma, a form of cancer. Her parents live in Kolkata but during the lockdown she has been working to procure medicines for her mother online or coordinating with pharmacists in that city on the phone. Her mothers monthly medication costs 20,000Purkayastha shares the expenses of the online orders.

Challenges such as these are significantly higher in a region like Kashmir. No stranger to state-imposed restrictions, Kashmir is presently dealing with a situation where only users with postpaid mobile phones have access to data, and that too at 2G speeds. This at a time when people around the world are working from home, using meeting apps, downloading informative videos or accessing information seamlessly.

Kashmiri journalist Shuja Ul Haq, 37, took his mother to Delhi in December, when she was diagnosed with leukaemia. After the initial rounds of chemotherapy, they returned to Kashmir in early March, just as the pandemic hit this part of the world. Today, one wants to get help, medical advice online but the speed of the internet is slow here so you cant really do that. It definitely creates an impedimentif you have to send documents to doctors, its hard, its slow. Sometimes it takes hours for pictures to load. But you have to keep at it, what else can one do?" he says.

Haq, whose parents stay with him, says he has managed to find a hospital where his mother can be treated. But every time they visit, they carry their own bedding and ensure she is covered head to toe, an attempt to protect her from the virus.

Some of the issues, of course, are universal. Healthcare is expensive, particularly for cancer.

Haqs father is an advocate but doesnt practise as much as he used to. There was insurance but it wasnt enough for a disease like this. To begin with, the extended family helped and the family managed the rest from their savings. But with global markets and economies down, Haq is worried. Now the economy is also very slow. You dont know whether your jobs are secure. If at all they are secure, you dont know if there will be salary cuts," he says. The fact is that a disease and illness like this needs money constantlyyou still have to get medicines, which is very expensive. You still have to go to the doctors. Its definitely a cause of concern. We are taking it one day at a time."

Feeling of helplessness

The addition of covid-19 worries is taking a toll on the mental health of millennials. Mental health expert and columnist Pooja Priyamvada says many of the queries on social media and helplines of late have come from millennials living abroad, expressing anxiety about the health and safety of parents in India.

She lists the consequences. There is often caregivers fatigue, which usually manifests in a lot of anxiety because you are constantly anxious about the other person. Then there are times when you are unable to provide that care for whatever reasonlike right now due to restricted mobility. A lot of times, due to this depression kicks in as well," says Priyamvada. She goes back to what Kessler believes is at the heart of what the world is experiencing through covid-19. You feel inadequate. There is anticipatory grief, you feel like their safety, security, medical safety might be compromised. There is a certain helplessness about it."

Purkayastha, for instance, has been suffering from clinical depression since her mothers diagnosis. Being at a distance takes its own mental toll as well. There is a continuous uncertainty thats lingering. You never know," says Purkayastha But being away can also be a blessing at times, as horrible as that may sound. People tend to take illnesses differently so I suppose a lot has improved since my parents moved to Kolkata, where they are surrounded by friends. But earlier, in our house, all conversation was only about disease and prolonged thoughts of death."

Changing relationships

According to a WHO report, Even in India, a country where strong family ties have often been assumed to continue, only 20% of households include people living in joint or extended families."

Just ahead of the lockdown, as the number of covid-19 cases in the country began to swell, Shivank Jhanjhi, a 27-year-old law graduate, moved from Delhi to Gwalior to be with his parents. His brother lives in Gurugram, so he knew he would have to be in Gwalior to organize medicinesthey are not easily available there, he says. Jhanjhi has been trying to organize medicines with the help of friends with dispensaries and pharmacies in the city.

In June 2018, when Jhanjhi was away on a fellowship in Karnataka, his mother was diagnosed with, and operated on for, breast cancerhis relationship with his parents has changed since.

When the chemo was going on, thats something which somewhat made a difference to me emotionally. Their (your parents) behaviour completely changes, you see them as children. So over the last two years since she was diagnosed, the equation changed. Earlier, it was them caring about me more and I wasnt really being responsible. But now its different," he says. When I was in Delhi applying for a clerkship and all this covid-19 news started pouring in, all I could think about was how vulnerable my mother is and also the news they are consuming, the habits they stick to. I had to get back home and be there."

This concern seems to be a common phenomenon among millennials, particularly those living away from their parents.

Purkayastha has gone from speaking to her parents once a day to calling at least three times a day. Every time something causes anxiety, they are on the phonewhether its the rising number of cases or her building being declared a red zone. The communication has increased manifold, she is more patient and understanding.

Chaudhary is working towards a long-term shift in their living situations. This is something I have started thinking about now even though its a very uncomfortable thing for me to think about. It involves taking some major life decisions, like getting a permanent home in Delhi where my parents can come and live with me for at least a few months in the year. They are getting old and I am the only child. Thats a big concern. I would prefer now if they move here at least for a few months of the year, I would like to see them more often. Psychologically, it would make a huge difference."


When the pandemic really hit home in mid-March, a common concern among millennials in urban set-ups, it appeared, was to keep their boomer parents indoors and ensure they followed social distancing protocols. The state-imposed lockdown, however, has made the vulnerabilities far more conspicuous, all-encompassinga gnawing worry.

From going out of their way to ensuring they dont infect their parents (frequent baths, changing clothes as soon as they get back home, making sure their parents eat right) to combating fake news, navigating hospital visits, worrying from a distance and trying their best to cope, the pandemic has changed the way they are viewing the elderly.

The balance, as Kessler points out in his interview to HBR, lies in shaping, not ignoring, anticipatory grief. The goal is to find balance in the things youre thinking. If you feel the worst image taking shape, make yourself think of the best image. We all get a little sick and the world continues. Not everyone I love dies. Maybe no one does because were all taking the right steps."

How covid-19 birthed the millennial caregiver - Livemint

Read the Rest...

Types of Respiratory Viral Infections – WTOP

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on Types of Respiratory Viral Infections – WTOP

Our bodies are always working hard to fight off infections. Viruses are just one cause of the infections we can

Our bodies are always working hard to fight off infections. Viruses are just one cause of the infections we can get. Different types of viruses can affect different parts of the body. One area of the body that can be affected by a virus is the respiratory system.

The respiratory system is the group of tissues and organs that allows us to breathe, bringing in oxygen-rich air and exhaling carbon dioxide. You breathe air in through your nose and mouth, which wet and warm the air. Then the air travels through your voice box, down your windpipe and though two tubes into your lungs.

Here, cilia, tiny mucus-covered hairs, trap foreign particles and germs to filter the air that you breathe. You then cough or sneeze those particles out of your body. The average set of lungs breathes in about 2,000 gallons of air every day.

The upper part of the respiratory tract includes:

The nose.

Nasal cavities.



Voice box, or larynx.

The lower respiratory tract includes:

The windpipe, also known as the trachea.

Bronchi, airways that branch off the trachea that circulate air in and out of the lungs.

A pair of lungs.

[READ: A Patients Guide to Respiratory Disease.]

Viruses of the Respiratory System

There are about 200 viruses known to cause disease in humans, says pediatric nurse practitioner Maryanne Tranter, founder of The Healthy Child Concierge in Columbus, Ohio.

Our respiratory system is especially vulnerable to certain viruses that can cause a cold, flu and other illnesses. Viruses are the smallest microorganism that can affect our cells and cause disease or illness, says pulmonologist and critical care medicine physician Dr. Ziad R. Mattar of Orlando Health in Orlando, Florida.

A respiratory viral infection refers to a virus that specifically affects the upper or lower respiratory tracts, or both. We typically get a respiratory viral infection through the mouth or nose via respiratory droplets, which are microscopic drops mostly made of water and produced when someone coughs, sneezes or talks. The viruses in these droplets are generally thought to be contagious if youre within 6 feet of the person who produces them. Viruses in droplets can live on surfaces for several hours, and you can get sick from touching those surfaces.

Those droplets, if coming from someone who is sick, can immediately start to infect and multiply in our cell linings, says Dr. Sudeb Dalai, an infectious disease specialist and clinical assistant professor with the Division of Infectious Diseases and Geographic Medicine at Stanford University Medical Center in Palo Alto, California.

The viruses that affect the respiratory system almost all have a similar structure, and they are all transmitted through respiratory droplets, Dalai says. They also are all seasonal, meaning that they emerge and make people sick during certain times of the year.

Viruses can affect the respiratory system differently, depending on where they initially attack. For instance, when a virus affects the lungs and airways, it can make breathing harder and cause wheezing, says Dr. Tina Q. Tan, an attending physician of infectious diseases?at Ann & Robert H. Lurie Childrens Hospital of Chicago and a professor of pediatrics at Northwestern University Feinberg School of Medicine.

A virus thats in the nose and nasal cavities can make you feel stuffy. Sometimes, these infections can affect other parts of the body. For instance, upper respiratory viral infections also can cause a viral ear infection because the ears and throat are connected by the eustachian tube, Tan says. An infection can cause that tube to become swollen or irritated, so fluid cant drain out of the ear properly. That fluid in the ear builds up and can lead to an infection.

There are many types of viruses that can lead to a respiratory viral infection. Some of the most common include:


Common cold.



COVID-19, which is technically known as severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2.


Respiratory syncytial virus, or RSV.

[SEE: Are Summer Colds Worse Than Winter Ones?]

The Common Cold

The common cold is not caused by just one virus. In fact, it can be caused by hundreds of different viruses, Tan says. Some of the viruses associated with the common cold include:

Coronaviruses. While one member might currently be most notorious for the illness that causes COVID-19, this is a large family of viruses. Four types are common and cause mild to moderate respiratory infections, like the common cold.

Enteroviruses. Infections caused by enteroviruses are more common in the summer and fall, according to the Centers for Disease Control and Prevention. In addition to the common cold, the enterovirus can potentially cause other health problems, such as low oxygen in the blood and conjunctivitis (a type of eye infection), according to the Enterovirus Foundation.

Rhinoviruses. Rhino means nose, so it may be no surprise that these types of infections are thought to be the cause of 30% to 35% of all common colds and the sniffling and sneezing that accompany them, according to the National Institutes of Health.

Symptoms associated with the common cold include:

A runny nose.



A sore throat.

Feeling more tired.

A fever.

Losing your voice (laryngitis).

A cold is usually diagnosed with a history and exam performed by a health professional. However, many colds are managed at home without a formal diagnosis.

Theres no cure for a cold. Thats why drinking fluids, resting, staying home and using pain relievers or medicines to help your congestion as needed are usually the best way to get over a cold.

[SEE: Flu vs. the Common Cold: Symptoms and Treatment.]

The Flu

Like the common cold, flu isnt caused by just one type of virus. Its primarily caused by viruses called influenza type A or influenza type B. The exact virus that causes most flu in any given flu season is a usually a subtype of influenza A or B.

The most common flu symptoms include:

A fever of 100.4 F or higher.

Chills or feeling overheated.

Congestion or a runny nose.




Muscle aches.

Not everyone who has the flu gets it diagnosed. However, those who do see a doctor for the flu may take one of several tests that help pinpoint that its the flu, according to the CDC. The results are available in as little as 15 minutes or in a few hours, depending on the test.

Those who are at higher risk for the flu and who suspect they have it should get tested for it, the CDC advises. Thats because they are more prone to flu complications. Higher-risk populations include:

Adults age 65 and older.


People with chronic conditions such as asthma, diabetes and heart disease.

Pregnant women.

Doctors may run tests to rule out other types of infections that have symptoms similar to the flu, Dalai says.

There are antiviral treatments for the flu that can reduce the number of days you are sick and help prevent serious flu complications, such as pneumonia, the CDC reports. Additionally, rest and maintaining a good fluid intake will help.

Getting the flu vaccine each year can help lower your risk and is effective 40% to 60% of the time, according to the CDC. That percentage can vary each year. Flu vaccines are important for people of all ages, as flu can lead to death. Among the 36 million to 56 million estimated flu illnesses in the U.S. from October 2019 to early April 2020, there were 24,000 to 62,000 deaths, the CDC reports in its preliminary estimates.


The new coronavirus is also called SARS-CoV-2 or COVID-19 and is caused by one strain of coronavirus. Thats why health experts call it the new coronavirus, indicating that this is not the first coronavirus affecting humans.

Symptoms of coronavirus usually appear within 2 to 14 days after exposure and include:

A fever.



Difficulty breathing.

Digestive symptoms, such as diarrhea.


Loss of taste or smell.

Muscle pain.

Sore throat.

Not everyone who has the new coronavirus has been tested or is able to get tested for it. Those who do usually take a test in which health experts collect a sample from the upper respiratory tract via the nose. Those in the hospital for the new coronavirus also may have a test called a bronchoscopy, which helps doctors see the lungs and airways. During this test, doctors also will collect a sample that can be tested in a lab.

There is no current treatment for the new coronavirus, although many studies are in progress. During a search of the terms COVID-19 or SARS-CoV-2 performed on the website in mid-April, Mattar found 621 trials underway. The trials involve a variety of medications types, including tocilizumab and anti-viral medications used to treat HIV, such as remdesivir. Although there are no results yet, the various trials should lead to some significant insights for those treating the virus, Mattar says.

[See: Common Childhood Respiratory Diseases]

Respiratory Syncytial Virus

RSV is more common in children, although adults can get it as well. It resembles a cold, but the severity of RSV symptoms depends on a childs age, Tranter says. Almost all children have had an RSV infection by age 2, according to the National Foundation for Infectious Diseases.

Those symptoms can include:

In infants younger than age 1: cough, difficulty breathing, fever and wheezing.

In younger children: wheezing thats diagnosed as bronchiolitis, which is an inflammation of the small breathing passageways in the lungs called bronchioles. However, this doesnt mean the child has asthma. They wheeze because their airways are already small, and the virus causes inflammation inside the airways, Tranter explains.

Older children often experience RSV as a cold or pneumonia. If they have asthma, the virus could make it worse.

In adults, RSV can cause cold-like symptoms, but they can become severe and are sometimes fatal in those who are older or those who have a weakened immune system or heart disease. This type of virus is thought to cause 177,000 hospitalizations in 14,000 deaths among those age 65 and over annually in the U.S., according to the NFID.

Health professionals will use a physical exam, which includes listening to the lungs, to help diagnose RSV. Other tests usually arent done unless a complication from RSV is suspected.

The best care for RSV is liquids, rest and alleviating symptoms with steamy bathrooms and cold-mist humidifiers, Tranter says. Children who develop severe RSV bronchiolitis also may need extra oxygen support and fluids. A vaccine for RSV is under development, but is not yet available, according to the CDC.

Preventing Infections

There are some tried-and-true ways to prevent getting any type of respiratory viral infection:

1. Wash your hands frequently, for at least 20 seconds.

2. Dont touch your face.

3. Stay at home when youre sick.

4. Cover your cough or sneeze with a tissue, and throw the tissue away. If a tissue isnt available, use your elbow to cover it, not the palm of your hand.

5. Routinely disinfect any surfaces that are touched often.

6. Follow any social distancing guidelines recommended by federal or local authorities.

7. Wear a face mask when youre sick.

Visit link:
Types of Respiratory Viral Infections - WTOP

Read the Rest...

Energy conservation may be a major function of sleep, says new research – Tdnews

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on Energy conservation may be a major function of sleep, says new research – Tdnews

Can staying up late make you fat? A growing body of research has suggested that poor sleep quality is linked to an increased risk of obesity by deregulating appetite, which in turn leads to more calorie consumption.

But a new study published this week in PLOS Biology found that the direction of this reaction might actually be flipped: Its not the sleep loss that leads to obesity, but rather that excess weight can cause poor sleep, according to researchers from the University of Pennsylvanias Perelman School of Medicine and the University of Nevada, Reno, who discovered their findings in the microscopic worm Caenorhabditis elegans (C. elegans).

We think that sleep is a function of the body trying to conserve energy in a setting where energetic levels are going down. Our findings suggest that if you were to fast for a day, we would predict you might get sleepy because your energetic stores would be depleted, said study co-author David Raizen, MD, PhD, an associate professor of Neurology and member of the Chronobiology and Sleep Institute at Penn.

Raizen emphasized that while these findings in worms may not translate directly to humans, C. elegans offer a surprisingly good model for studying mammalian slumber. Like all other animals that have nervous systems, they need sleep. But unlike humans, who have complex neural circuitry and are difficult to study, a C. elegans has only 302 neurons one of which scientists know for certain is a sleep regulator.

In humans, acute sleep disruption can result in increased appetite and insulin resistance, and people who chronically get fewer than six hours of sleep per night are more likely be obese and diabetic. Moreover, starvation in humans, rats, fruit flies, and worms has been shown to affect sleep, indicating that it is regulated, at least in part, by nutrient availability. However, the ways in which sleeping and eating work in tandem has remained unclear.

We wanted to know, what is sleep actually doing? Short sleep and other chronic conditions, like diabetes, are linked, but its just an association. Its not clear if short sleep is causing the propensity for obesity, or that the obesity, perhaps, causes the propensity for short sleep, said study co-author Alexander van der Linden, PhD, an associate professor of Biology at the University of Nevada, Reno.

To study the association between metabolism and sleep, the researchers genetically modified C. elegans to turn off a neuron that controls sleep. These worms could still eat, breathe, and reproduce, but they lost their ability to sleep. With this neuron turned off, the researchers saw a severe drop in adenosine triphosphate (ATP) levels, which is the bodys energy currency.

That suggests that sleep is an attempt to conserve energy; its not actually causing the loss of energy, Raizen explained.

In previous research, the van der Linden lab studied a gene in C. elegans called KIN-29. This gene is homologous to the Salt-Inducible Kinase (SIK-3) gene in humans, which was already known to signal sleep pressure. Surprisingly, when the researchers knocked out the KIN-29 gene to create sleepless worms, the mutant C. elegans accumulated excess fat resembling the human obesity condition even though their ATP levels lowered.

The researchers hypothesized that the release of fat stores is a mechanism for which sleep is promoted, and that the reason KIN-29 mutants did not sleep is because they were unable to liberate their fat. To test this hypothesis, the researchers again manipulated the KIN-29 mutant worms, this time expressing an enzyme that freed their fat. With that manipulation, the worms were again able to sleep.

Raizen said this could explain one reason why people with obesity may experience sleep problems. There could be a signaling problem between the fat stores and the brain cells that control sleep, he said.

While there is still much to unravel about sleep, Raizen said that this paper takes the research community one step closer to understanding one of its core functions and how to treat common sleep disorders.

There is a common, over-arching sentiment in the sleep field that sleep is all about the brain, or the nerve cells, and our work suggests that this isnt necessarily true, he said. There is some complex interaction between the brain and the rest of the body that connects to sleep regulation.

Additional authors on this paper include Jeremy Grubbs and Lindsey Lopes, who completed this research while students at the University of Nevada, Reno and the Perelman School of Medicine, respectively.

This study was funded by the National Institutes of Health grants R01NS107969 and R01NS088432, COBRE P20GM103650, and the National Science Foundation grant IOS1353014.

More here:
Energy conservation may be a major function of sleep, says new research - Tdnews

Read the Rest...

What Is Hemopure? The Blood Substitute That Could Save Lives – Men’s Health

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on What Is Hemopure? The Blood Substitute That Could Save Lives – Men’s Health

ANTWAN PIPER WAS at dinner with colleagues on a work trip in Oklahoma when his wife, Alexis, called from back home in Texas. He figured he would call her back later, but then she called again. On the third call, he finally picked up. Alexis sounded out of breath and in pain, her voice tight. Ive already called the ambulance, she managed to get out.

It was Sunday, March 4, 2018, and Alexis was in crisisa term for when her sickle-cell anemia flares up. Due to this congenital condition, Alexiss red blood cellsnormally round and flexiblebecome rigid and sticky, and twist into a sickle-like shape, rendering them poor at carrying oxygen, job number one for red blood cells. They clump together and can get stuck in small blood vessels, blocking blood flow and oxygen in certain parts of the body, which causes excruciating pain.

Except this time felt different, far worse than ever before. In the span of several hours, Alexis had gone from feeling like she had a cold to experiencing shooting pain throughout her body, leaving her crumpled on the floor of their upstairs hallway. Antwan served as a master sergeant in the Air Force and a church pastor, while his wife, a former teacher, wrote upbeat and inspirational religious books.

Both were generally healthy and in their mid-30s, and they always tried to stay positive. At the moment, however, both were terrified. I dont think words can do it justice, the feeling of a husband hearing his wife in pain and he cant do anything about it, Antwan says.

When Alexis arrived at Brooke Army Medical Center, outside San Antonio, the doctors quickly went through the usual protocols for a sickle-cell patient in crisis, ultimately electing to give her a transfusion. They checked her blood type, found a match, and tapped a fresh bag of red blood cells into her IV, hoping they would diffuse among the damaged ones. After a few days of additional treatment, her doctors decided to give her another transfusion to try to raise her level of hemoglobin, a blood protein that transports oxygen. During this second transfusion, Alexis began writhing and screaming. The pain was unbearablea ten out of ten, she says.

Alexiss hematologist, Lauren Lee, M.D., recognized the problem immediately: The patient had been receiving transfusions since age seven. Now shed entered a potentially fatal state of hyperhemolysis, a condition in which the immune system attacks red blood cells, believing them to be an invading pathogen, which further hampers fresh oxygen transportation to strangled cells.

A healthy persons hemoglobin level is 12 to 15 grams per deciliter. Because of her condition, Alexiss typical level was 7, but it had dropped to about 5 by the time she was admitted. It kept falling as she slipped in and out of consciousness and hospital staff rushed her to the ICU.

By the time Antwan reached her bedside, things looked bleak. Alexiss hemoglobin level had dropped into the 2-to-3 range, and she was very weak. Thats when they started prompting me, preparing me for her dying, he says. Theyre telling me theres been no survivors among patients with such a low hemoglobin level.

But Dr. Lee had one last idea. She got in touch with two top hematologistsMarc Zumberg, M.D., and Colonel Andrew Cap, M.D., Ph.D.and everyone thought one risky intervention might still be worth a shot. It was a transfusion of, well, not blood exactly but rather an approximation called Hemopure, a synthetic blood-like product made from cow blood.

Because Hemopure is not actual blood, it could theoretically be given to just about anyone. Its shelf stable and adaptive to any blood type. Gin up enough and you could have it on tap in ambulances and Army-medic backpacks, just about anywhere you might need a lifesaving transfusion on demand.

The catch: Hemopure has not yet been approved by the FDA. In the U.S. its only available through compassionate use, for patients with life-threatening conditions who have exhausted all other treatment options. Dr. Lee said there was no guarantee that it would work, and no guarantee that it would be free of side effects. All it had to do was deliver oxygen throughout Alexiss body until she was well enough to start making her own blood cells. Dr. Lee asked Antwan if he was interested, and he said he wanted to pray over it. Its either this or she dies, she remembers saying. We wanted to give it a shot.

Antwan agonized over all of these thoughts as he prayed. They told me what they were hoping it would do, but they couldnt guarantee me that it would work, he says. We were exhausted, and we didnt have time. I really struggled, because of the uncertainty and the side effects they really didnt know. He couldnt ask Alexis since she was unresponsive. It was all up to him.

He signed the consent.

LATE ONE NIGHT, Zaf Zafireliss phone started beeping and buzzing. He picked it up, knowing immediately what kind of call this would be: another desperate surgeon inquiring about Hemopure, the blood substitute made by the company he ran. Zafirelis was CEO of a tiny biotech outfit called Hemoglobin Oxygen Therapeutics, which had been operating on a shoestring but had recently secured space to open a new manufacturing facility across the street from a slaughterhouse in Pennsylvania.

He was used to getting three or four calls a week, always about patients whom conventional interventions had failed, always in the direst of straits. One time, it was a young man on Long Island with a rectal hemorrhage. Another, a 28-year-old woman in Michigan who needed risky heart surgery. Then there was the 35-year-old patient with anemia as a result of her leukemia. And the man in his 70s with a potentially fatal GI bleed.

Sometimes these calls came from doctors with patients who had severe anemia and no options, like Alexis. Often they involved patients who could not receive blood transfusions because of their religious beliefs, like Jehovahs Witnesses, whose interpretation of the Bible prohibits ingesting the blood of their fellow man.

After a short talk with Dr. Lee, Zafirelis shipped ten units of Hemopure via emergency medical courier straight to San Antonio. He knew from experience that it could give her a shot. The product will keep a patient who needs oxygen alive almost for as long as needed, he says somewhat carefully.

Hemopure and products like it first came about as a response to the HIV/AIDS crisis of the 1980s, when many patients were unwittingly infected with the virus via blood transfusions. That led to a rush by several companies to transcend science fiction with a safe, pathogen-free alternative to natural blood.

The problems with traditional blood supplies are fairly straightforward. You can run out, donations can be tainted with pathogens, and the stuff doesnt last that long outside the bodyeven chilled, youve got just a few weeks before packed red blood cells lose effectiveness.

Beginning in the late 80s, scientists set out to come up with a replacement that would be not only disease-free but also stable without refrigeration. Whoever invented it certainly stood to prosper. That was like the Holy Grail of blood, says Kendall Crookston, M.D., Ph.D., a professor of medicine at the University of New Mexico School of Medicine. But they pushed it from the bench into clinical trials perhaps too quickly.

Two early formulations emerged, both focused on doing bloods main job of transporting oxygen from the lungs to cells. The first was a red and syrupy class of artificial hemoglobin-based oxygen carriers (HBOCs) that replicated the action of red blood cells. The second was a milky set of compounds called perfluorocarbons, which transported oxygen chemically. By the early aughts, there were more than half a dozen products in various stages of development. But during clinical trials for two products, PolyHeme (an HBOC) and Oxygent (a perfluorocarbon), people died and trials were halted. Investors fled, and the sector promptly tanked.

Hemopure survived, but barely. Unlike the other HBOCs, it was made from cow blood and not expired human blood. It contained no actual red or white blood cells, plasma, lipoproteins, or any other ingredient of the complex cocktail that is human blood. Instead, it delivered oxygen via hemoglobin made by separating the red blood cells out of cow blood, then lysing or chemically piercing them to produce microscopic hemoglobin molecules. Further (and proprietary) processing and polymerization rendered the hemoglobin into a solution easily processed by the body.

Hemopure lacked many of the properties of whole bloodit didnt clot or create new antibodies. Could it keep you from bleeding out? Maybe, so long as your body caught up and eventually took over the healing process. But Zafirelis, who helped pioneer Hemopure at a company called Biopure, didnt like how market speculation seemed to gloss over the drawbacks. He left the company in 1995. Its an unreasonable comparison, he says. Theres no way an artificial product can match what the real thing does.

The SEC alleged that, starting in 2003, Biopure had failed to publicly disclose that the FDA had put a hold on a clinical trial of the product in emergency-room trauma patients due to safety concerns. The companys stock crashed, and three executives were indicted for making false representations about the health of the venture. Zafirelis was brought back as CEO in 2004 and helped popularize a veterinary HBOC version that has saved dogs, tropical parrots, an African rhino (through penile infusion), even a shark at a Vegas casino.

But the worst was yet to come. In April 2008, The Journal of the American Medical Associationpublished a meta-analysis of clinical trials of five HBOC products, including Hemopure, partially funded by the Washington, D.C., public-interest group Public Citizen. The authors added up the fatalities in the treatment and control groups from hundreds of combined treatments and concluded that these products actually increased a patients risk of heart attack and possibly death because they scavenge nitric oxide, a blood-borne gas that causes blood vessels to expand. Without it, blood vessels constrict. Thats a danger, but so is dying while doing nothing.

In 2009, the venture was sold to a new set of investors, who kept Zafirelis on board to see if they could resurrect the dream. They downsized dramatically and were trying to figure out how to reboot. Zafireliss company was on life support.

THE TEN UNITS of Hemopure reached the hospital less than 24 hours after Dr. Lee called Zafirelis. Unlike blood, which is shipped in ice-packed coolers, it arrived in a simple cardboard box. Each plastic bag inside sloshed with 250 milliliters of a dark-red liquid whose color reminds Zafirelis more of cabernet sauvignon than of actual blood.

Brooke Army Medical Centers care team hitched the bag to Alexiss IV, and its contents began to flow in. Whereas blood can take some time to start working, artificial hemoglobin transports oxygen quickly. And because the molecules are so tiny, about one-thousandth the size of red blood cells, they could easily filter into Alexiss partially blocked blood vessels. Dr. Lee and the rest of the team watched as her hemoglobin level stabilized and then slowly began to climb.

Meanwhile, Dr. Lee gave Alexis other drugs and vitamins that she hoped would help her body begin to produce its own red blood cells again, as well as another experimental drug to stop the inflammatory reaction that was breaking down her existing red blood cells.

Over the next day or so, they infused another unit of Hemopure, and another, and another. Alexis woke up. By about the fourth bag, she was able to have a conversation, Dr. Lee recalls. She looked the best she had ever looked.

When the fifth bag was tapped, all that changed instantly. Alexiss eyes fluttered and she started violently seizing, not just once but over and over. Dr. Lee wondered if Alexis was receiving too much oxygen, so she stopped the treatment and the seizures halted. Alexiss hemoglobin level was dropping again.

Antwan had to face the same question with even higher stakes: Keep trying or let her go? Would he allow them to continue the Hemopure treatment on his wife, even if it risked causing more seizuresand possibly brain damage?

ZAFIRELIS HAS ZERO uncertainty about why he continues to pursue the dream of substitute blood, and why it matters. He thinks its time to drop comparisons and reset expectations completely. The mistake that previous companies made was that they started claiming this was artificial blood, which its notits red cells only, Zafirelis says. This is where the industry hype ran away from science. (So much so that in 2007, Danish cyclist Michael Rasmussen was forced to quit the Tour de France while in the leaders yellow jersey because hed somehow secured Hemopure as a performance enhancer. It was useless, he later tweeted. Pure placebo.)

Zafireliss plan is to test Hemopure in situations in which real blood simply doesnt make sense, by working with the military (which receives FDA priority for the development of lifesaving medical products) and patients who have no alternative left. The Department of Defense recently committed $8.2 million to study Hemopure in up to 1,600 pre-hospital trauma patients in South Africa, where ambulance-transport times are far longer than the 11-minute average in the U.S. and clean blood is in short supply.

In fact, Hemopure has been approved for hospital use in South Africa for decades. It has a very good safety record over 20 years, but we dont have a lot of data for its use in trauma situations, which is why we want to do this study, says Lee Wallis, M.D., the head of the division of emergency medicine at both the University of Cape Town and Stellenbosch University, who is in charge of the project.



Bruce Spiess, M.D., a professor of anesthesiology at the University of Florida, points out the broader potential for doctors in emergency situations throughout the developing world, where blood is sparse and diseases are harder to control.

Zafirelis is also working with a consortium of U.S. medical institutions, including the University of Michigan, Duke University, the University of Texas Southwest Medical Center, and the University of Rochester, to look at future applications of products like Hemopure. Thats part of a $4.8 million National Institutes of Health study examining the overall impact of those last-ditch interventions, even if they fail. Its often a choice between giving patients something and giving them nothing, says Dr. Crookston.

But in the eyes of the FDA, the notion of substitute blood is a hypothesis that still needs testingand some patients are in the unenviable position of being able to help with that. Their unfortunate health issues offer opportunities for doctors to learn new ways of assisting others. To not take advantage of that prolongs the inability to help those in similar situations. Thats part of why Zafirelis still answers his phone every time, but also why hes encouraging less invasive experiments with just as much potential.

Hemopure stands to revolutionize not just critical and emergency care but transplants, too. In 2014, for instance, a Dutch transplant surgeon named Robert Porte requested Hemopure for a study testing how a perfusion system that circulates fluids might recondition 16 donated livers that had been initially declined for regular transplantation. After the treatment, 11 were deemed viable and were successfully transplanted into patients who had no other option for treating their advanced liver disease. These patients were severely ill at the time, but all 11 of them (and their livers) were doing fine six months later.

Normally, transplant surgeons weigh the risks and make a call: Is this organ healthy enough to help the recipient survive? There is no way you can do a test drive, Dr. Porte says. You cant take a risk with a patients life, so you have to err on the safe side. At the same time, people are dying on the wait list because we dont have enough good organs.

If Dr. Portes findings pan out, he estimates that the technique could increase the supply of available livers by 20 percent. In the meantime, Wake Forest University and the Cleveland Clinic are studying the implications for hand and limb transplants. And the journal Nature recently shared a study that shows perfusion with Hemopure can revive dead pig-brain cells, something that might eventually help stroke victims.

Tests on live pigs reveal that Hemopure may also affect ischemiain which blocked blood vessels may damage the heart or the brainby bringing oxygen there more quickly and efficiently than real blood can. In each case, the promise of a cure-all is being more narrowly defined, strategically sharpened, and potentially firmed up for more investment. Through success and, yes, sometimes failure, Zafirelis has learned that Hemopure can deliver oxygen to tissues and keep them alive outside of the body, in some cases more effectively than natural blood. You have to do it under the right conditions, he says.

"WE DON'T KNOW what kind of condition shell be in, Antwan remembers the doctors telling him. We wont know how much or the degree of brain damage she may have suffered until she wakes up or starts moving around. He wanted to pray again. There is no time to pray, they told him. You have to decide now.

After talking to a friend from church, Antwan decided that Alexiss best chance was to keep going. Alexis received a sixth unit of Hemopure, enough to sustain her until her body could begin producing its own red blood cells with their own hemoglobin. Shortly after the last dose drained in, she was placed in a medically induced coma to prevent further seizures and assist her body with recovery. But even after her condition stabilized and she woke up, she faced a long and difficult road.

Alexis spent six weeks total in the hospital, often feeling foggy and confused. When her hemoglobin climbed back to 5.5around the same level as when she was admittedshe was discharged to keep recuperating at home.

The oxygen-deprived state had damaged her muscles and motor skills, so she spent several months in physical and cognitive therapy with a home nurse, learning to walk again. Antwan took time off from work to be with her as she recovered. He doesnt regret his decision to use Hemopure, and Alexis doesnt, either. Shes back working on her books and views the experience as nothing short of a miracle: Im grateful that God could use something that hadnt been done before and allow it graciously to help me in a very tough time and an ugly, life-threatening situation.

Zafirelis remains hopeful. He recently got a call from a 19-year-old male Jehovahs Witness in North Carolina with sickle-cell disease, who received 23 units of Hemopure. Another came from a 28-year-old man in Nebraska with sickle-cell complications cascading into pneumonia, respiratory failure, and acute congestive heart failure. He received 27 units over the course of more than two weeks. Both survived. All told, more than $1 billion has been invested in research and development for Hemopure, and the product has saved more than 400 people in life-or-death situations. That survival rate should only increase with more chances.

This has become my lifes work now, Zafirelis says. I cannot give up. I believe in it. Ive seen it work. Hes ready to pull more bags out of storage the next time the phone rings.

Read this article:
What Is Hemopure? The Blood Substitute That Could Save Lives - Men's Health

Read the Rest...

Assessing the Fallout From the Coronavirus Pandemic Spinal Muscular Atrophy Medicine Market Global Industry Analysis, Trends and Forecast, 2019-2027…

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on Assessing the Fallout From the Coronavirus Pandemic Spinal Muscular Atrophy Medicine Market Global Industry Analysis, Trends and Forecast, 2019-2027…

Analysis of the Global Spinal Muscular Atrophy Medicine Market

The presented report on the global Spinal Muscular Atrophy Medicine market offers valuable insights related to the future prospects of the Spinal Muscular Atrophy Medicine market. The study evaluates the various parameters that are expected to influence the growth of the Spinal Muscular Atrophy Medicine market over the forecast period including the current trends, regulatory framework, and evolving policy structure across different regions. The impact of the COVID-19 pandemic on the global Spinal Muscular Atrophy Medicine market along with the projected plan of action is included in the presented study.

As per the study, the Spinal Muscular Atrophy Medicine market is poised to exceed the value of ~US$XX by the end of 2019 and grow at a CAGR of ~XX% during the considered forecast period, 20XX-20XX. The growth opportunities for established and emerging market players, drivers of the market, and existing challenges in the Spinal Muscular Atrophy Medicine market are thoroughly analyzed. Although the market is expected to witness a slow growth rate in the first half of the forecast period due to the COVID-19 pandemic, market growth is expected to gather momentum in the second half.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @

Spinal Muscular Atrophy Medicine Market Bifurcation

By Region

The regional assessment included in the Spinal Muscular Atrophy Medicine market sheds light on the scenario of the Spinal Muscular Atrophy Medicine market in various geographies. The scope of growth, market share, size, and future prospects of the Spinal Muscular Atrophy Medicine market in each regional market is illustrated in the report along with informative graphs and figures.

By Product Type

The product adoption assessment sheds light on the pricing structure, supply-demand ratio and the innovations involved in each product.

Market Segment AnalysisThe research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by Type, the Spinal Muscular Atrophy Medicine market is segmented intoLMI-070ND-602NT-1654NusinersenNXD-30001Others

Segment by ApplicationHospitalClinicOthers

Global Spinal Muscular Atrophy Medicine Market: Regional AnalysisThe Spinal Muscular Atrophy Medicine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the Spinal Muscular Atrophy Medicine market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EGlobal Spinal Muscular Atrophy Medicine Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.The major players in global Spinal Muscular Atrophy Medicine market include:Astellas Pharma Inc.AveXis, Inc.Bioblast Pharma Ltd.Cytokinetics, Inc. 24F. Hoffmann-La Roche Ltd.GenethonGenzyme CorporationGMP-Orphan SASIonis Pharmaceuticals, Inc.Longevity Biotech, IncNeurodyn Inc.Neurotune AGNovartis AGSarepta Therapeutics, Inc.Voyager Therapeutics, Inc.Vybion, Inc.WAVE Life Sciences Ltd.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]

Competitive Assessment

The completion landscape of the Spinal Muscular Atrophy Medicine market is accurately depicted in the report. The report includes the company profiles of some of the leading companies in the Spinal Muscular Atrophy Medicine market wherein the product portfolio, pricing structure, and market share of each company is provided.

Vital Information that can be drawn from the Spinal Muscular Atrophy Medicine Market Report

You can Buy This Report from Here @

The report aims to address the following queries related to the Spinal Muscular Atrophy Medicine market:

Go here to see the original:
Assessing the Fallout From the Coronavirus Pandemic Spinal Muscular Atrophy Medicine Market Global Industry Analysis, Trends and Forecast, 2019-2027...

Read the Rest...

COVID-19, A lesson for Science and Society – The Indian Awaaz

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on COVID-19, A lesson for Science and Society – The Indian Awaaz

By Dr. Seyed Ehtesham Hasnain

COVID-19 pandemic has shaken human lives in an unprecedented manner. Never before in the history of humanity has any threat had affected every domain of our existence. The deadly virus has attacked the very notion of ManThe Social Animal. Interestingly we are being saved by non-drug interventions such as quarantine, social distancing, hand washing, and for health-care workers masks and other protective equipment.

The greatly reduced COVID-19 infection burden and even mortality seen in many parts of the world where BCG (Bacillus Calmette-Guerin) vaccination has been the widely used practice, may not just be a coincidence. BCG was originally developed against Tuberculosis (TB) and this hundred-year-old TB vaccine offers broad protection and sharply reduce the incidence of respiratory infections.

Three weeks after the pandemic was declared by the WHO, it is increasingly clear from the Covid-19 data that countries which have been practicing universal BCG vaccination are relatively giving a better to fight to SARS-CoV-2 which could be BCGS trained immunity effect.

The effect of Covid-19 as per a recent report in the journal Science, the disease can attack almost anything in the body with devastating consequences.

We are all hoping for a vaccine in 2021. But what do we do in the meantime? And more importantly we will have to live with the threat of coronavirus for the foreseeable future and adapt accordingly because there is no guarantee a vaccine can be developed immediately. The biggest lesson that we learn out of the COVID-19 pandemic is to be remain protected indoors, distancing socially.

Three ways how Science will get us through the COVID-19 Pandemic: The modern frontiers: Within just weeks of the first reported case, scientists had not only identified by microscopic the virus responsible for the disease, but had sequenced its entire genome.

The curiosity-driven foundations: There is value, intrinsically, to knowing something about any aspect of the natural world. The curiosity-driven research of evolutionary virologists, of disease ecologists, of biophysicists, and scientists across many other fields of inquiry not only informs clinicians and policymakers, but also every cutting-edge piece of research at the frontiers of the field today.

The edge of fundamental: This is the most powerful knowledge in all of science; the fundamental limits of whats physically possible. Scientists are constantly working to push the limits of whats known. Scientific investments need to occur not only on the front lines of the current crisis, but on a wide-variety of curiosity driven, frontiers including at fundamental level itself.

Scientific lessons to be learntCovid-19 early genome annotation led to key knowledge transfer allowing vaccine developments and efforts in drug design.However, some neo characteristics of Covid-19 has left a void and could be addressed by thorough interventions.We are living in extraordinary times that call for united efforts, as these problems are much too complex in magnitude and scale for anyone to solve alone. The Information Storm that COVID-19 is raising globally is rather difficult to cope with.

Research at Jamia HamdardEarlier research at the JH Institute of Molecular Medicine showed that the SARS-CoV-2 has very high transmissibility and that SARS-CoV-2s inherent feature of viral aggregation increases its survivability and fitness, a property that will likely help in viral persistence and becoming endemic.

Analyses of about 4000 clinical isolates of SARS-CoV-2, including 25 isolates sequenced in India (largest such comparative study ever done till date globally), showed that Indian isolates are not unique, they all cluster along isolates from other continents, Europe and North America highlighting spill over from these nations. Mutation analyses revealed highest variation in Spike, Envelope protein and ORF1a and that each amino acid in constituent ORFs has undergone mutation an observation which has major Implications in diagnosis and vaccine development. He also flagged the low infection and mortality figures in India and wondered at the possibility of this to be BCGs Trained Immunity effect.

Impact on World PoliticsThe pandemic has global political effects as more suffering is ahead for the developing world. Pandemic is shaking bedrock assumptions about US exceptionalism and the likely global leadership void waiting to be filled. Debate rages over ideology, power blocs, social inequalities and distribution of wealth across the world. Though nothing could be predicted, yet world leaders, policymakers and analysts have started talking about the shape of the new situation emerge post-Corona.

Dr. Seyed Ehtesham Hasnain is a noted scientist and Vice-Chancellor of Jamia Hamdard

View post:
COVID-19, A lesson for Science and Society - The Indian Awaaz

Read the Rest...

Global C Difficile Infection Drug Market 2020 Global Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand And Leading Players…

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on Global C Difficile Infection Drug Market 2020 Global Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand And Leading Players…

Recent report on C Difficile Infection Drug Market Size by Application, By Types, By Regional Outlook Global Industry Analysis, Share, Growth, Opportunity, Latest Trends, and Forecast to 2025.

The new report offers a powerful combination of latest, in-depth research studies on the C Difficile Infection Drug market. The authors of the report are highly experienced analysts and possess deep market knowledge.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures):

Major Players Analyzed Under This Report are:

MerckAstellasEli LillyANI PharmaceuticalFlynn PharmaAspen PharmacareAkornMerus labsPfizerAstraZenecaStridesSanofiFreseniusXelliaZhejiang MedicineLupin

C Difficile Infection Drug Players/Suppliers Profiles and Sales Data: Company, Company Basic Information, Manufacturing Base and Competitors, Product Category, Application and Specification with Sales, Revenue, Price and Gross Margin, Main Business/Business Overview.

Table Of Content

Market Overview: Scope & Product Overview, Classification of C Difficile Infection Drug by Product Category (Market Size (Sales), Market Share Comparison by Type (Product Category)), C Difficile Infection Drug Market by Application/End Users (Sales (Volume) and Market Share Comparison by Application), Market by Region (Market Size (Value) Comparison by Region, Status and ProspectC Difficile Infection Drug Market by Manufacturing Cost Analysis:Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis

Key Benefits for Stakeholders

The study provides an in-depth analysis of the C Difficile Infection Drug market size along with the current trends and future estimations to elucidate the imminent investment pockets.Information about key drivers, restraints, and opportunities and their impact analysis on the market size is provided.Porters five forces analysis illustrates the potency of buyers and suppliers operating in the portable gaming industry.The quantitative analysis of the C Difficile Infection Drug industry from 2020 to 2026 is provided to determine the C Difficile Infection Drug market potential.

C Difficile Infection Drug Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the C Difficile Infection Drug market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Get Customized Report in your Inbox within 24 hours:

Market Segment Analysis

The research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type MetronidazoleVancomycinFidaxomycinOthers

Segment by Application Pre-treatmentMid-term treatmentOthers

C Difficile Infection Drug Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

C Difficile Infection Drug Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the C Difficile Infection Drug market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2025. These analyses will help the reader to understand the potential worth of investment in a particular region.

Key Strategic Developments:The study also includes the key strategic developments of the C Difficile Infection Drugmarket, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, market share, CAGR, and gross margin.Analytical Tools: The C Difficile Infection Drug Market report includes the precisely studied and weighed data of the key industry players and their scope in the C Difficile Infection Drug market by means of several analytical tools

Read More Report:

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email: [emailprotected]



See the article here:
Global C Difficile Infection Drug Market 2020 Global Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand And Leading Players...

Read the Rest...

Nanomedicine Market: Industry Analysis and forecast 2026 – Research Columnist

§ April 25th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Market: Industry Analysis and forecast 2026 – Research Columnist

Nanomedicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.


The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.


Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.


Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at:

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage



Contact: +919607065656/ +919607195908


Read this article:
Nanomedicine Market: Industry Analysis and forecast 2026 - Research Columnist

Read the Rest...

Diabetes Reversed in Mice With CRISPR-Edited Stem Cells From Patients – Technology Networks

§ April 24th, 2020 § Filed under Nano Medicine Comments Off on Diabetes Reversed in Mice With CRISPR-Edited Stem Cells From Patients – Technology Networks

Using induced pluripotent stem cells produced from the skin of a patient with a rare, genetic form of insulin-dependent diabetes calledWolfram syndrome, researchers transformed the human stem cells into insulin-producing cells and used the gene-editing tool CRISPR-Cas9 to correct a genetic defect that had caused the syndrome. They then implanted the cells into lab mice and cured the unrelenting diabetes in those mice.

The findings, from researchers at Washington University School of Medicine in St. Louis, suggest the CRISPR-Cas9 technique may hold promise as a treatment for diabetes, particularly the forms caused by a single gene mutation, and it also may be useful one day in some patients with the more common forms of diabetes, such as type 1 and type 2.

The study is published online April 22 in the journal Science Translational Medicine.

Patients with Wolfram syndrome develop diabetes during childhood or adolescence and quickly require insulin-replacement therapy, requiring insulin injections multiple times each day. Most go on to develop problems with vision and balance, as well as other issues, and in many patients, the syndrome contributes to an early death.

This is the first time CRISPR has been used to fix a patients diabetes-causing genetic defect and successfully reverse diabetes, said co-senior investigatorJeffrey R. Millman, PhD, an assistant professor of medicine and of biomedical engineering at Washington University. For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene. But we see this as a stepping stone toward applying gene therapy to a broader population of patients with diabetes.

Wolfram syndrome is caused by mutations to a single gene, providing the researchers an opportunity to determine whether combining stem cell technology with CRISPR to correct the genetic error also might correct the diabetes caused by the mutation.

A few years ago, Millman and his colleagues discovered how to convert human stem cells into pancreatic beta cells. When such cells encounter blood sugar, they secrete insulin. Recently, those same researchers developed a new technique to more efficiently convert human stem cells into beta cells that are considerably better at controlling blood sugar.

In this study, they took the additional steps of deriving these cells from patients and using the CRISPR-Cas9 gene-editing tool on those cells to correct a mutation to the gene that causes Wolfram syndrome (WFS1). Then, the researchers compared the gene-edited cells to insulin-secreting beta cells from the same batch of stem cells that had not undergone editing with CRISPR.

In the test tube and in mice with a severe form of diabetes, the newly grown beta cells that were edited with CRISPR more efficiently secreted insulin in response to glucose. Diabetes disappeared quickly in mice with the CRISPR-edited cells implanted beneath the skin, and the animals blood sugar levels remained in normal range for the entire six months they were monitored. Animals receiving unedited beta cells remained diabetic. Their newly implanted beta cells could produce insulin, just not enough to reverse their diabetes.

We basically were able to use these cells to cure the problem, making normal beta cells by correcting this mutation, said co-senior investigatorFumihiko Urano, MD, PhD, the Samuel E. Schechter Professor of Medicine and a professor of pathology and immunology. Its a proof of concept demonstrating that correcting gene defects that cause or contribute to diabetes in this case, in the Wolfram syndrome gene we can make beta cells that more effectively control blood sugar. Its also possible that by correcting the genetic defects in these cells, we may correct other problems Wolfram syndrome patients experience, such as visual impairment and neurodegeneration.

In the future, using CRISPR to correct certain mutations in beta cells may help patients whose diabetes is the result of multiple genetic and environmental factors, such as type 1, caused by an autoimmune process that destroys beta cells, and type 2, which is closely linked to obesity and a systemic process called insulin resistance.

Were excited about the fact that we were able to combine these two technologies growing beta cells from induced pluripotent stem cells and using CRISPR to correct genetic defects, Millman said. In fact, we found that corrected beta cells were indistinguishable from beta cells made from the stem cells of healthy people without diabetes.

Moving forward, the process of making beta cells from stem cells should get easier, the researchers said. For example, the scientists have developed less intrusive methods, making induced pluripotent stem cells from blood and they are working on developing stem cells from urine samples.

In the future, Urano said, we may be able to take a few milliliters of urine from a patient, make stem cells that we then can grow into beta cells, correct mutations in those cells with CRISPR, transplant them back into the patient, and cure their diabetes in our clinic. Genetic testing in patients with diabetes will guide us to identify genes that should be corrected, which will lead to a personalized regenerative gene therapy.


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Visit link:
Diabetes Reversed in Mice With CRISPR-Edited Stem Cells From Patients - Technology Networks

Read the Rest...

‘Silent hypoxia’ may be killing COVID-19 patients. But there’s hope. –

§ April 24th, 2020 § Filed under Nano Medicine Comments Off on ‘Silent hypoxia’ may be killing COVID-19 patients. But there’s hope. –

As doctors see more and more COVID-19 patients, they are noticing an odd trend: Patients whose blood oxygen saturation levels are exceedingly low but who are hardly gasping for breath.

These patients are quite sick, but their disease does not present like typical acute respiratory distress syndrome (ARDS), a type of lung failure known from the 2003 outbreak of the SARS coronavirus and other respiratory diseases. Their lungs are clearly not effectively oxygenating the blood, but these patients are alert and feeling relatively well, even as doctors debate whether to intubate them by placing a breathing tube down the throat.

The concern with this presentation, called "silent hypoxia," is that patients are showing up to the hospital in worse health than they realize. But there might be a way to prevent that, according to a New York Times Op-Ed by emergency department physician Richard Levitan. If sick patients were given oxygen-monitoring devices called pulse oximeters to monitor their symptoms at home, they might be able to seek medical treatment sooner, and ultimately avoid the most invasive treatments.

Related: Are ventilators being overused on COVID-19 patients?

"This is not a new phenomenon," said Dr. Marc Moss, the division head of Pulmonary Sciences and Critical Care Medicine at the University of Colorado Anschutz Medical Campus. There are other conditions in which patients are extremely low on oxygen but don't feel any sense of suffocation or lack of air, Moss told Live Science. For example, some congenital heart defects cause circulation to bypass the lungs, meaning the blood is poorly oxygenated.

However, the increased understanding that people with COVID-19 may show up with these atypical coronavirus symptoms is changing the way doctors treat them.

Normal blood-oxygen levels are around 97%, Moss said, and it becomes worrisome when the numbers drop below 90%. At levels below 90%, the brain may not get sufficient oxygen, and patients might start experiencing confusion, lethargy or other mental disruptions. As levels drop into the low 80s or below, the danger of damage to vital organs rises.

However, patients may not feel in as dire straits as they are. A lot of coronavirus patients show up at the hospital with oxygen saturations in the low 80s but look fairly comfortable and alert, said Dr. Astha Chichra, a critical care physician at Yale School of Medicine. They might be slightly short of breath, but not in proportion to the lack of oxygen they're receiving.

There are three major reasons people feel a sense of dyspnea, or labored breathing, Moss said. One is something obstructing the airway, which is not an issue in COVID-19. Another is when carbon dioxide builds up in the blood. A good example of that phenomenon is during exercise: Increased metabolism means more carbon dioxide production, leading to heavy breathing to exhale all that CO2.

Related: Could genetics explain why some COVID-19 patients fare worse than others?

A third phenomenon, particularly important in respiratory disease, is decreased lung compliance. Lung compliance refers to the ease with which the lungs move in and out with each breath. In pneumonia and in ARDS, fluids in the lungs fill microscopic air sacs called alveoli, where oxygen from the air diffuses into the blood. As the lungs fill with fluid, they become more taut and stiffer, and the person's chest and abdominal muscles must work harder to expand and contract the lungs in order to breathe.

This happens in severe COVID-19, too. But in some patients, the fluid buildup is not enough to make the lungs particularly stiff. Their oxygen levels may be low for an unknown reason that doesn't involve fluid buildup and one that doesn't trigger the body's need to gasp for breath.

Exactly what is going on is yet unknown.

Chichra said that some of these patients might simply have fairly healthy lungs, and thus have the lung compliance (or elasticity) so not much resistance in the lungs when a person inhales and exhales to feel like they are not short on air even as their lungs become less effective at diffusing oxygen into the blood. Others, especially geriatric patients, might have comorbidities that mean they live with low oxygen levels regularly, so they're used to feeling somewhat lethargic or easily winded, she said.

Related: 11 surprising facts about the respiratory system

In the New York Times Op-Ed on the phenomenon, Levitan wrote that the lack of gasping might be due to a particular phase of the lung failure caused by COVID-19. When the lung failure first starts, he wrote, the virus may attack the lung cells that make surfactant, a fatty substance in the alveoli, which reduces surface tension in the lungs, increasing their compliance. Without surfactant, the increased surface tension causes the alveoli to deflate, but if they are not filled with fluid,, they won't feel stiff, Levitan wrote. This could explain how the alveoli fail to oxygenate the blood without the patient noticing the need to gasp for more air.

The virus might also create hypoxia by damaging the blood vessels that lead to the lungs, Moss said. Normally, when a patient has pneumonia, the tiny blood vessels around the fluid-filled areas of the lungs constrict (called hypoxic vasoconstriction): Sensing a lack of oxygen in the damaged areas, the body shunts blood to other, healthier parts of the lungs. Because pneumonia fills the lungs with fluid, the person will feel starved for air and gasp for breath. But their vessels send the blood to the least-damaged parts of the lung, so their blood oxygenation stays relatively high, given the damage.

In COVID-19, that balance may be off. The lungs aren't very fluid-filled and stiff, but the blood vessels don't constrict and reroute blood to the least-damaged spots. People feel free to inhale and exhale without resistance, but the blood is still trying to pick up oxygen at alveoli that are damaged and inefficient.

"What is most likely happening here is that hypoxic vasoconstriction is lost for some reason, so that blood does flow to places where there is some damage to the lungs," Moss said. It could also be a combination of factors, he added.

"I'm not going to say the alveoli are normal and the surfactant is normal, but when someone has hypoxia out of proportion to what you would see in the lung, that makes lung specialists think there is a problem on the blood vessel side," he said.

In the New York Times, Levitan suggests that patients who are not sick enough to be admitted to the hospital be given pulse oximeters, devices that clamp to the finger to measure blood oxygenation. If their oxygenation numbers start to fall, it could be an early warning sign to seek medical treatment.

"It's an intriguing possibility," Moss said.

Even without widespread at-home oxygen monitoring, doctors are now starting to differentiate between patients who have low oxygen levels and who are working hard to breathe, and those who have low oxygen levels but are breathing without distress, Chichra said. Early in the pandemic, knowing that COVID-19 patients can start to fail quickly, physicians tended to put people with hypoxia on ventilators quickly. Now, Chichra said, it's becoming clear that patients who aren't struggling for breath often recover without being intubated. They may do well with oxygen delivered via nasal tube or a non-rebreather mask, which fits over the face to deliver high concentrations of oxygen.

Hypoxic patients who are breathing quickly and laboriously, with elevated heart rates, tend to be the ones who need mechanical ventilation or non-invasive positive-pressure ventilation, Chichra said. The latter is a method that uses a face mask instead of a tube down the throat, but also uses pressure to push air into the lungs.

"The key difference we've found between these folks is that the people who are working hard to breathe are the folks who usually need to be intubated," Chichra said.

Originally published on Live Science.

The rest is here:
'Silent hypoxia' may be killing COVID-19 patients. But there's hope. -

Read the Rest...

« Older Entries Newer Entries »

Page 10«..9101112..2030..»